Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2020-07-08 Share Issue/Capital Cha…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharma announces intention to carry out a placing of new ordinary shares
Share Issue/Capital Change Classification · 95% confidence The document is a press release announcing Hansa Biopharma's intention to conduct a capital raise through an accelerated bookbuild placing of new ordinary shares. It details the purpose of the capital injection, the engagement of financial advisors, and includes preliminary financial data for H1 2020. This falls under the category of capital and financing updates, as it describes a specific fundraising activity and the issuance of new shares.
2020-07-08 English
Hansa Biopharma avser att genomföra en riktad nyemission av stamaktier
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Hansa Biopharma announcing the intention to conduct a directed share issue (a capital raise) via an accelerated bookbuilding process. It details the purpose of the capital, the involvement of investment banks, and includes preliminary financial figures for the first half of 2020 to support the offering. Since this is an announcement of a new share issuance and capital raising activity, it falls under the 'Share Issue/Capital Change' category.
2020-07-08 Swedish
Hansa Biopharma ingår exklusivt avtal med Sarepta Therapeutics för utveckling och kommersialisering av imlifidase som förbehandling inför genterapi i utvalda indikationer
M&A Activity Classification · 99% confidence The document is a press release dated July 2, 2020, announcing a significant exclusive agreement between Hansa Biopharma and Sarepta Therapeutics regarding the development and commercialization of imlifidase as a pretreatment for gene therapy. This announcement details financial terms (upfront payment, milestones, royalties) and strategic collaboration. This type of announcement, detailing a major business transaction, partnership, or financing activity, aligns best with the 'Capital/Financing Update' category, although it is primarily a business development announcement. Since there is no specific category for 'Business Development' or 'Collaboration Agreement,' I must evaluate the closest fit. It involves significant financial commitments and potential future revenue streams, making 'CAP' (Capital/Financing Update) a plausible fit, or potentially 'RNS' (Regulatory Filings) as a general announcement. However, given the focus on the financial structure of the deal (payments, royalties), 'CAP' is slightly more specific than the general 'RNS' fallback. Since it is a formal announcement of a major deal structure, and not a report itself, it is not an ER, IR, or 10-K. It is not a management change (MANG) or a dividend (DIV). It is a major corporate transaction announcement. In many classification schemes, major licensing/collaboration deals involving significant upfront payments and milestones are grouped under financing/capital activities. I will classify it as 'CAP' due to the explicit mention of financial terms and milestones, which are capital-related aspects of the agreement. If 'CAP' is too narrow, 'RNS' would be the fallback, but 'CAP' captures the essence of the financial structure of the deal.
2020-07-02 Swedish
Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications
Earnings Release Classification · 92% confidence The document is titled "PRESS RELEASE" and announces a major business development: an exclusive licensing agreement between Hansa Biopharma and Sarepta Therapeutics regarding the drug imlifidase. It details financial terms (upfront payment, milestones, royalties) and the strategic rationale. Crucially, it concludes by announcing a related "Conference Call" with dial-in details. This structure—a press release announcing a significant corporate event (licensing/partnership) followed by details of an associated call—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a full financial report (10-K, IR) or a transcript of the call itself (CT), and it focuses on a major business transaction rather than just management commentary (MDA), it fits best as an Earnings Release (ER) if this announcement coincided with a reporting period, or a general Regulatory Filing (RNS) if it's purely transactional. However, the presence of a scheduled conference call strongly suggests this is the primary communication vehicle for significant news, often accompanying or substituting for a formal ER/MDA when the news is transactional. Given the options, a major corporate announcement detailing financial implications and followed by a call is most closely aligned with an Earnings Release (ER) structure, even if the core news is a partnership, as these often serve as the primary vehicle for material updates outside of mandated periodic reports. Alternatively, since it is a press release about a partnership, it could be classified as RNS, but ER is often used for material financial news releases. I will lean towards ER as it contains specific financial metrics and milestones, which are core to earnings communications. Q3 2020
2020-07-02 English
Hansa Biopharma receives positive CHMP opinion for Idefirix[TM] (imlifidase) for kidney transplant in EU
Regulatory Filings Classification · 100% confidence The document is titled '# PRESS RELEASE' and announces a significant regulatory event: 'Hansa Biopharma receives positive CHMP opinion for Idefirix (imlifidase) for kidney transplant in EU'. It details the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding conditional approval. This type of announcement, which communicates a key regulatory decision or milestone outside of routine financial reporting (like 10-K or ER), typically falls under general Regulatory Filings (RNS) or potentially an Investor Presentation (IP) if it were a slide deck. Given the format is a press release focused on a regulatory outcome and pipeline updates, and it explicitly states it is information the company is 'obliged to make public pursuant to the EU Market Abuse Regulation,' RNS (Regulatory Filings) is the most appropriate general category for such market-sensitive, non-standard financial disclosures. It is not a formal financial report (10-K, IR), a management discussion (MDA), or a specific capital action (CAP, SHA).
2020-06-25 English
Hansa Biopharma erhåller positivt CHMP-utlåtande för Idefirix[TM] (imlifidase) för njurtransplantation inom EU
Regulatory Filings Classification · 100% confidence The document is a 'PRESSMEDDELANDE' (Press Release) from Hansa Biopharma dated June 25, 2020. It announces that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has issued a positive opinion recommending conditional marketing authorization for their drug Idefirix (imlifidase). This is an announcement regarding a significant regulatory milestone (positive opinion/recommendation) for a drug candidate, which is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). It is a specific regulatory/company update. Since it is an announcement about a regulatory decision/opinion, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a formal communication to the market about regulatory progress, rather than a specific financial filing type like 10-K or a management/board change (MANG). Given the context of regulatory news, RNS is the most appropriate general regulatory announcement category.
2020-06-25 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.